Merck Upgrades Guidance After Strong Second-Quarter Performance

Merck has upgraded its full-year guidance due to strong second-quarter performance. The company's Group net sales increased to €5.4 billion, representing organic growth of 4.1% compared with the year-earlier quarter.

This growth was driven by continued demand in Process Solutions, Rare Diseases, and Semiconductor Solutions as well as disciplined execution and ongoing investments in research and innovation. Merck's Life Science business delivered strong growth, with all three business units contributing to organic growth and broad-based momentum across regions.

The company's proposed acquisition of Bio-Techne Corporation, USA, will further strengthen its leadership in high-growth life science markets and support its ambition to provide integrated workflow solutions across the scientific value chain. Merck benefits from its longstanding region-for-region approach built on close customer relationships and deep local market expertise.